Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology for treating oncogene amplified cancers, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Zachary Hornby will engage in a fireside chat on Monday, June 9, at 9:20 a.m. ET in Miami, FL. The company will provide a live webcast of the session, which will also be archived and available in the Investors section of their website under Events & Presentations.

SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference.

The fireside chat session is scheduled for Monday, June 9, in Miami, FL, at 9:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s next ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) that has been evaluated in a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications. Boundless Bio is also conducting IND-enabling studies of BBI-940, a potentially first-in-class orally bioavailable, potent Kinesin degrader. Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and X.

Contacts:
James Lee, Boundless Bio
jlee@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) presenting at the Goldman Sachs Healthcare Conference 2025?

Boundless Bio will present on Monday, June 9, 2025, at 9:20 a.m. ET in Miami, FL.

Who will represent Boundless Bio (BOLD) at the Goldman Sachs Healthcare Conference?

Zachary Hornby, President and Chief Executive Officer of Boundless Bio, will participate in a fireside chat at the conference.

Where can I watch Boundless Bio's (BOLD) presentation at the Goldman Sachs Conference?

A live and archived webcast will be available in the Events & Presentations section of Boundless Bio's website under the Investors tab.

What type of company is Boundless Bio (BOLD)?

Boundless Bio is a clinical-stage oncology company that focuses on extrachromosomal DNA (ecDNA) biology to develop therapies for oncogene amplified cancers.